Vikas Sinha - 20 May 2025 Form 4 Insider Report for Verona Pharma plc (VRNA)

Role
Director
Signature
/s/ Andrew Fisher, Attorney-in-fact for Vikas Sinha
Issuer symbol
VRNA
Transactions as of
20 May 2025
Net transactions value
-$1,422,320
Form type
4
Filing time
22 May 2025, 16:06:12 UTC
Previous filing
06 May 2025
Next filing
05 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sinha Vikas Director 3 MORE LONDON RIVERSIDE, LONDON, UNITED KINGDOM /s/ Andrew Fisher, Attorney-in-fact for Vikas Sinha 22 May 2025 0001337845

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRNA Ordinary Shares Options Exercise $80,608 +160,000 +215% $0.5038 234,440 20 May 2025 Direct F1
transaction VRNA Ordinary Shares Sale $1,502,928 -160,000 -68% $9.39 74,440 20 May 2025 Direct F1, F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRNA Share Options (Right to Buy) Options Exercise $0 -160,000 -100% $0.000000 384 20 May 2025 Ordinary Shares 160,000 $0.5038 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2 The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2024.
F3 The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from $9.375 to $9.4263, inclusive (or $75.00 to $75.41 per ADS, inclusive). The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3.
F4 Consists of 74,440 Ordinary Shares represented by 9,305 ADSs.
F5 The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F6 The option is fully vested.